Tower Research Capital (TRC)’s Immunome IMNM Stock Holding History
Bought
Maintained
Sold
Other funds holding IMNM
Tower Research Capital (TRC)'s IMNM Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Immunome (IMNM) stake by 7.4% in Q3 2026, selling an estimated $12.6K and leaving 6,339 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2620.
Tower Research Capital (TRC) first reported a position in IMNM in Q4 2020 and has held it in 20 quarters since. The position peaked at $446K in Q1 2026. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.
- Tower Research Capital (TRC) held 6,339 shares of Immunome worth $136K as of Q3 2026.
- Tower Research Capital (TRC) sold 508 Immunome shares in Q3 2026, an estimated $12.6K.
- Immunome made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #2620 holding.
- Tower Research Capital (TRC) first reported a position in Immunome in Q4 2020 and has held it in 20 quarters since.
- Tower Research Capital (TRC)'s Immunome position peaked at $446K in Q1 2026.
- 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.